The interleukin-33 antibody of AnaptysBio passes midstage test in asthma
The pipeline drug, etokimab of AnaptysBio, has positive data in a third indication that adds asthma to one of its triumphs. The US-based company gets another proof-of-concept study for the interleukin-33 (IL-33) inhibitor, because of phase 2a trial in severe eosinophilic asthma, and a third phase 2b program that will be set up and commence soon. The study was conducted with only 25 patients, who received a single intravenous dose of etokimab (ANB020), however, the antibody company showed that the anti-IL-33 drug had a quick impact on lung function that lasted for about two months.
FDA uplifts ho...
